JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

TRANSFERSOMES: VESICULAR CARRIERS FOR ENHANCED TRANSDERMAL DRUG DELIVERY

[1]Mr. Omkar Pawar, [2]Ms. Mohini Yadav, [3]Dr. Vijaykumar Kale, [4]Dr. Mahesh Thakare, [5]Mr. Vaibhav Narwade
[1]Student, [2]Assistant Professor, [3]Principal, [4]Associate Professor, [5]Assistant Professor,
[1]Department of B. Pharmacy,
[1]Kasturi Shikshan Sanstha College of Pharmacy, Shikrapur, India.

ABSTRACT: Transdermal drug delivery systems (TDDS) have emerged as innovative therapeutic approaches offering numerous advantages including avoidance of first-pass hepatic metabolism, sustained plasma drug concentrations, improved patient compliance, and reduced systemic side effects. However, the stratum corneum barrier fundamentally restricts the transdermal permeation of most therapeutic agents, particularly those with high molecular weights or poor lipophilicity. Transfersomes represent a revolutionary advance in vesicular carrier technology, designed specifically to overcome these physiological limitations through their exceptional ultradeformability and flexibility. These ultradeformable lipid vesicles consist of phospholipids combined with specialized edge activators (single-chain surfactants), enabling them to traverse the skin's microscopic pathways while maintaining structural integrity. The unique composition imparts remarkable elasticity, allowing transfersomal vesicles to squeeze through pores and intercellular channels much smaller than their own size. This comprehensive review critically examines the fundamental principles, mechanisms of action, formulation strategies, characterization methodologies, and clinical applications of transfersomes in transdermal drug delivery. The review synthesizes current knowledge regarding the osmotic gradient-driven penetration mechanisms, physicochemical properties optimizing penetration efficiency, and the stability considerations essential for pharmaceutical development. Furthermore, this review highlights diverse pharmaceutical applications ranging from pain management to hormone replacement therapy, while addressing manufacturing challenges and regulatory considerations that impact their commercial viability. Transfersomes represent a paradigm shift in non-invasive drug delivery, offering unprecedented potential for delivering complex therapeutic molecules across biological barriers with enhanced bioavailability and reduced dose-dependent adverse effects.

Keywords: Transfersomes, Transdermal drug delivery, Ultradeformable liposomes, Edge activators, Vesicular carriers, Skin penetration enhancement

1. INTRODUCTION

Transdermal drug delivery systems have become increasingly significant in contemporary pharmaceutical practice, representing an evolution beyond conventional oral and parenteral administration routes[1]. These innovative systems exploit the skin's inherent physiological characteristics to achieve controlled, sustained therapeutic drug delivery across the stratum corneum barrier[7]. The transdermal route provides several well-documented advantages, including circumvention of gastrointestinal incompatibilities, avoidance of hepatic first-pass metabolism, maintenance of steady-state plasma drug concentrations, and enhanced patient compliance through non-invasive administration[8]. Traditional transdermal approaches, however, face significant limitations due to the skin's remarkably effective barrier function. The stratum corneum, comprising approximately fifteen to twenty layers of keratinized corneocytes embedded within a lipophilic matrix of ceramides, cholesterol, and free fatty acids, presents a formidable obstacle to drug permeation[9]. This "brick and mortar" organizational architecture restricts passive diffusion of most pharmaceutical agents, particularly molecules exceeding five hundred Daltons in molecular weight or those demonstrating poor lipid solubility[10].

The quest to overcome these physiological constraints has driven pharmaceutical research toward innovative carrier systems and penetration enhancement technologies[11]. Among these advances, transfersomes have emerged as a transformative solution, representing a sophisticated refinement of conventional liposomal technology. Transfersomes, also termed ultradeformable liposomes or elastic vesicles, were pioneered by Cevc and Blume as a response to the recognized limitations of standard liposomal carriers in transdermal applications[12]. The fundamental innovation involves the strategic incorporation of edge activators—single-

chain amphiphilic surfactants such as sodium cholate, Tween 80, or Span 80—into the phospholipid bilayer[13]. This compositional modification fundamentally alters the membrane's mechanical properties, conferring unprecedented flexibility and deformability[14]. The resultant vesicular architecture enables spontaneous deformation and passage through skin pores significantly smaller than the vesicle's resting diameter, a capability entirely absent in conventional liposomes[15].

The scientific rationale underlying transfersomal efficacy lies in their exploitation of the natural transepidermal osmotic gradient. The skin maintains an inherent hydration gradient, with the outer stratum corneum exhibiting only 10-20% water content compared to 75-80% water content in the viable epidermis and dermis[16]. This moisture gradient creates a thermodynamic driving force that propels transfersomal vesicles deeper into skin layers through a process termed "osmotic self-propulsion"[17]. This passive yet highly efficient penetration mechanism occurs without requiring external energy sources or invasive procedures, distinguishing transfersomes from alternative enhancement technologies[18]. Consequently, transfersomes represent a paradigm shift in transdermal drug delivery science, enabling non-invasive delivery of pharmaceutically diverse molecules ranging from small hydrophobic compounds to large peptides and proteins[19].

2. STRUCTURAL COMPOSITION AND FORMULATION COMPONENTS



Fig 1: Transfersome Structure

2.1 Phospholipids: The Bilayer Foundation

Transfersomal formulations fundamentally depend upon carefully selected phospholipid components that form the vesicular bilayer architecture[1]. Natural and synthetic phospholipids including soybean phosphatidylcholine (SPC), egg phosphatidylcholine (EPC), and their derivatives constitute the primary structural components[7]. These amphiphilic molecules spontaneously self-assemble into bilayered structures when hydrated, creating an aqueous compartment suitable for drug encapsulation[8]. The fatty acid chain composition and degree of saturation significantly influence membrane fluidity and phase transition temperatures, thereby impacting vesicular stability and deformability characteristics[2]. Optimal lipid selection necessitates consideration of the target drug's physicochemical properties, storage requirements, and desired release kinetics[3].

2.2 Edge Activators: The Deformability Determinant

Edge activators represent the transformative component distinguishing transfersomes from conventional liposomes, fundamentally determining the vesicular deformability and penetration capacity[4]. These single-chain surfactants, typically employed at concentrations representing 5-25% (w/w) of total lipid content, function as bilayer destabilizers that reduce interfacial tension and increase membrane fluidity[5]. Commonly utilized edge activators include anionic surfactants (sodium cholate, sodium deoxycholate), nonionic surfactants (Tween 80, polysorbate 80, Span 80), and cationic surfactants (stearylamine)[6]. The selection of specific edge activators profoundly influences transfersomal characteristics including particle size, zeta potential, drug entrapment efficiency, and deformability index[9].

Research demonstrates that sodium cholate and sodium deoxycholate produce smaller transfersomal vesicles with higher zeta potential values compared to Tween 80-containing formulations[10]. Conversely, Tween 80 exhibits superior deformability characteristics due to its highly flexible, non-bulky hydrocarbon chains[11]. The hydrophile-lipophile balance (HLB) value of edge activators correlates directly with their capacity for drug encapsulation, with lower HLB values typically conferring superior entrapment efficiency[12]. Careful optimization of edge activator type and concentration constitutes a critical formulation parameter requiring individual assessment for each specific therapeutic agent[13].

2.3 Cholesterol and Stabilizing Agents

Cholesterol may be incorporated as an optional membrane component, functioning to modulate lipid packing density and enhance bilayer mechanical stability[14]. However, elevated cholesterol concentrations paradoxically reduce membrane elasticity, potentially compromising the deformability essential for transfersomal efficacy[15]. Additionally, stabilizing agents including cryoprotectants (sucrose, trehalose), antioxidants (α-tocopherol), and antimicrobial preservatives are frequently incorporated to enhance formulation shelf-life and prevent oxidative degradation of phospholipids[16]. These excipients become particularly crucial for lyophilized transfersomal formulations intended for extended storage[4].

3. MECHANISM OF TRANSDERMAL PENETRATION



Fig 2: Transdermal Penetration Mechanism

3.1 Osmotic Gradient-Driven Penetration

The fundamental penetration mechanism underlying transfersomal efficacy relies upon the transepidermal water activity gradient and osmotic forces[1]. When a transfersomal formulation is applied to skin, water evaporation from the applied product creates an osmotic stress differential[17]. This osmotic gradient, originating from the relatively dry stratum corneum (10-20% water content) adjacent to the more hydrated viable epidermis (75-80% water content), generates a powerful thermodynamic driving force[18]. The transfersomal vesicles respond to this osmotic gradient through spontaneous migration toward the hydrated region in a process termed "osmotic pull" or "self-propulsion," occurring passively without requirement for external energy input[20]. This elegant mechanism enables continuous, sustained vesicular penetration and drug delivery throughout the formulation application period[12].

3.2 Ultradeformability and Mechanical Flexibility

The exceptional membrane elasticity conferred by edge activators enables transfersomes to deform reversibly and traverse intercellular pathways substantially smaller than their resting vesicular diameter[19]. The lowered interfacial tension reduces the

energetic requirement for membrane deformation, allowing vesicles to elongate, compress, or assume alternative configurations while maintaining structural integrity[21]. This ultradeformable characteristic facilitates passage through skin pores measuring 20-50 nanometers in width, intercellular lipid channels, and corneocyte interstices, pathways normally impermeable to conventional rigid liposomes[13]. The deformability index, quantified as the ratio of pre-extrusion to post-extrusion vesicle size following passage through polycarbonate filters, serves as a quantitative measure of this critical parameter[14]. Deformability ratios exceeding 1.5 indicate substantial elastic deformation capacity[4].

3.3 Lipid-Skin Interactions and Barrier Disruption

Upon contact with stratum corneum lipids, transfersomal vesicles engage in dynamic interactions including fusion, adsorption, and lipid exchange processes[15]. The structural similarity between transfersomal phospholipids and endogenous skin lipids promotes mutual miscibility and spontaneous lipid intermixing[6]. This interaction temporarily fluidizes the tightly packed stratum corneum lipid matrix, enhancing local permeability through controlled disruption of the "brick and mortar" organization[7]. Additionally, edge activators further disrupt lipid packing by reducing their phase transition temperatures and increasing fluidity, facilitating deeper vesicular penetration without causing irreversible barrier damage[16]. The reversible nature of these interactions preserves long-term skin barrier integrity, a crucial consideration for safety and tolerability[17].

3.4 Transcellular and Intercellular Penetration Pathways

Transfersomes penetrate skin via both intercellular pathways (between corneocytes) and transcellular pathways (through corneocytes)[18]. The extraordinary deformability enables adaptive shape-shifting to accommodate the tortuous geometry of intercellular lipid channels, facilitating efficient passage with minimal resistance[19]. Concurrently, the phospholipid composition enables transient membrane fusion with corneocyte plasma membranes, enhancing transcellular transport through temporary membrane destabilization[20]. This dual-pathway penetration mechanism, unique among vesicular carriers, contributes to the exceptional drug deposition efficiency in deeper epidermal and dermal layers[9]. Once within viable epidermis or dermis, transfersomal vesicles release their drug cargo through diffusion or environment-induced rupture, establishing localized drug reservoirs sustaining prolonged therapeutic levels[21].

4. PREPARATION METHODOLOGIES

4.1 Thin Film Hydration Method

The thin film hydration technique, also designated rotary evaporation-sonication method, represents the conventional and most extensively utilized transfersome preparation methodology[1]. Phospholipids and edge activators are dissolved in volatile organic solvents (typically chloroform-methanol at 2:1 v/v ratio) within a round-bottom flask[7]. The organic solvent is subsequently evaporated at elevated temperature (above the lipid transition temperature) under reduced pressure using a rotary vacuum evaporator, yielding a thin, uniform lipid film[8]. Following complete solvent removal through overnight vacuum exposure, the dried film is rehydrated with aqueous buffer solution (typically pH 6.5-7.4) through manual rotation at controlled temperature and duration[9]. Hydrophilic drug molecules may be incorporated during this hydration step[20]. The resulting vesicular dispersion undergoes sonication utilizing either bath or probe sonicators to reduce vesicle size and improve uniformity[15]. Final homogenization is achieved through extrusion passages (typically 5-10 cycles) through sandwiched polycarbonate membranes (200 nm and 100 nm pore sizes), yielding monodisperse transfersomal populations with defined size parameters[16].

4.2 Alternative Preparation Methods

Modified handshaking technique involves vortexing the aqueous buffer solution, followed by gradual dropwise addition of the ethanolic phospholipid and edge activator mixture while continuous vortexing, generating a cloudy transfersomal suspension[4]. Subsequent sonication and extrusion steps proceed analogously to the thin film method[5]. The reverse-phase evaporation method employs a water-in-oil emulsion approach, wherein aqueous drug solution is emulsified within organic solvent containing lipids, followed by controlled evaporation to induce vesicle formation[6]. The ethanol injection method introduces an ethanolic phospholipid solution rapidly into aqueous buffer under vigorous stirring, promoting instantaneous vesicle formation through solvent displacement[7]. Each methodology presents distinct advantages and limitations regarding scalability, reproducibility, and suitability for different drug classes[8].

5. CHARACTERIZATION AND EVALUATION PROCEDURES

5.1 Vesicle Size and Polydispersity Assessment

Dynamic light scattering (DLS) instrumentation quantifies the mean vesicle diameter (z-average) and polydispersity index (PDI), critical parameters determining skin penetration capacity and batch consistency[1]. Optimal transfersomal diameter typically ranges from 100-300 nanometers, balancing penetration efficiency with colloidal stability[9]. PDI values below 0.3 indicate acceptable size uniformity, while values exceeding 0.5 suggest significant heterogeneity requiring formulation optimization[10]. Transmission electron microscopy (TEM) examination provides ultrastructural visualization, confirming spherical or slightly ellipsoidal

morphology, intact bilayer architecture, and absence of aggregation or fusion[11]. TEM analysis additionally determines lamellarity (unilamellar versus multilamellar) and reveals surface characteristics essential for understanding vesicle-skin interactions[12].

5.2 Zeta Potential and Colloidal Stability

Zeta potential measurement via electrophoretic mobility quantifies the electrical surface charge, predicting colloidal stability and potential biological interactions[1]. More negative zeta potential values (typically exceeding -30 millivolts) indicate superior electrostatic repulsion between vesicles, enhancing dispersal stability and reducing aggregation propensity[24]. Values between -20 to -30 millivolts represent moderate stability, while values approaching zero mV suggest significant aggregation risk and potential formulation shelf-life limitations[6]. The zeta potential measurement protocol requires sample dilution to achieve optimal optical density, thermal equilibration at 25 ± 0.5°C, and application of controlled electrophoretic voltage typically ranging from 20-40 volts[7].

5.3 Drug Entrapment Efficiency Analysis

Encapsulation efficiency determination quantifies the percentage of drug molecules successfully incorporated within the transfersomal bilayer and aqueous compartment[10]. The ultracentrifugation method involves sedimenting transfersomal vesicles at 20,000 rpm for 30 minutes at 4°C, separating non-encapsulated drug remaining in the supernatant from vesicle-associated drug in the pellet[11]. Quantification via high-performance liquid chromatography (HPLC) analysis of both fractions enables calculation of encapsulation efficiency using the formula: Encapsulation Efficiency (%) = [(Total Drug - Free Drug) / Total Drug] × 100[12]. Typical encapsulation efficiencies range from 70-95%, dependent upon the drug's lipophilicity and the formulation composition[13]. Hydrophilic drugs demonstrate lower encapsulation within the lipid bilayer but may preferentially localize in the aqueous core, while lipophilic compounds partition extensively into the phospholipid bilayer[14].

5.4 Membrane Elasticity and Deformability Index

The deformability index quantifies the vesicles' mechanical capacity to undergo reversible deformation, assessed through an extrusion method[15]. Transfersomal dispersions undergo size measurement via DLS prior to extrusion (pre-extrusion size = R_pre), followed by passage through polycarbonate filter membranes under controlled pressure (typically 2.5 bar), and subsequent size re-measurement (post-extrusion size = R_post)[16]. The deformability index is calculated as: Deformability Index = [Weight of Dispersion × R_pre] / [R_post × Pore Size], with values exceeding 1.5 indicating substantial elastic deformation capacity[4]. Minimal size increase post-extrusion (typically <10%) coupled with stable drug entrapment (>95%) confirms membrane integrity and excellent deformability[17].

5.5 Fourier Transform Infrared Spectroscopy

FTIR analysis employing attenuated total reflection (ATR) accessories evaluates drug-excipient compatibility and identifies potential chemical interactions[5]. Spectral analysis of pure drug, blank transfersomes, drug-loaded transfersomes, and physical mixtures enables detection of peak shifts (typically <5 cm^{-1}), peak disappearance, or appearance of new absorption bands indicating incompatibility[18]. Characteristic drug peaks persisting in drug-loaded formulations indicate physical rather than chemical association[19]. Slight peak shifting may reflect hydrogen bonding interactions without implying degradation, whereas substantial spectral alterations suggest incompatibility requiring formulation redesign[20].

6. PHARMACEUTICAL APPLICATIONS

6.1 Transdermal Pain Management

Transfersomes have demonstrated exceptional efficacy in delivering potent analgesics across the skin barrier for chronic and acute pain conditions[21]. Fentanyl-loaded transfersomal patches provide superior transdermal delivery compared to conventional formulations, maintaining steady-state plasma concentrations suitable for severe cancer pain management[6]. Buprenorphine transfersomal formulations enable non-invasive opioid analgesic delivery for chronic pain therapy, improving patient compliance through reduced dosing frequency[7]. Non-steroidal anti-inflammatory drugs including diclofenac, ketoprofen, and indomethacin demonstrate enhanced skin penetration and local anti-inflammatory activity when formulated as transfersomes, reducing systemic exposure and associated gastrointestinal toxicity[8].

6.2 Hormone Replacement Therapy

Transfersomal delivery of estrogen and testosterone provides consistent hormonal levels suitable for managing menopausal symptoms and male hypogonadism, while avoiding hepatic first-pass metabolism that reduces oral bioavailability[9]. Progesterone-loaded transfersomal formulations maintain stable hormonal levels for menstrual cycle regulation and pregnancy support[10]. The sustained-release characteristics inherent to transfersomal carriers eliminate fluctuations in plasma hormone concentrations associated with conventional replacement therapies, enhancing therapeutic outcomes and reducing adverse effects[11].

6.3 Cardiovascular and Hypertension Management

Nitroglycerin-loaded transfersomal patches provide improved therapeutic outcomes in angina pectoris management through sustained transdermal delivery, avoiding the cutaneous vasodilation and tachyphylaxis observed with conventional nitrate patches[12]. Clonidine transfersomal formulations enable controlled hypertension therapy with reduced systemic side effects through direct dermal drug deposition[13]. The non-invasive transdermal route improves patient compliance and enables dose adjustments through simple patch removal, advantages unavailable with oral medications[14].

6.4 Neurological and Psychiatric Disorders

Rivastigmine transfersomal patches improve cognitive function in Alzheimer's disease through enhanced transdermal delivery of this reversible acetylcholinesterase inhibitor, achieving superior bioavailability compared to oral formulations[15]. Selegiline transfersomal formulations provide monoamine oxidase inhibition for depression management with improved safety profiles through reduced systemic exposure[16]. Methylphenidate transfersomal patches enable non-invasive attention deficit hyperactivity disorder therapy with sustained therapeutic concentrations[17].

7. CHALLENGES AND FUTURE PERSPECTIVES

7.1 Stability Challenges

Transfersomal formulations face significant stability challenges during manufacturing and storage, including phospholipid oxidation, hydrolysis-induced membrane disruption, vesicle aggregation, and encapsulated drug leakage[1]. Extended storage at room temperature or elevated temperatures promotes hydrolysis of phosphoester bonds in the lipid bilayer, compromising membrane integrity and releasing encapsulated drugs prematurely[27]. Oxidation of unsaturated fatty acid chains within phospholipids generates reactive peroxide species capable of degrading both lipids and encapsulated pharmaceuticals[18]. Refrigerated storage (2-8°C) and freeze-dried formulations with appropriate cryoprotectants substantially extend shelf-life while maintaining vesicular properties[19].

7.2 Regulatory and Manufacturing Considerations

The regulatory pathway for transfersomal products requires comprehensive documentation including manufacturing process validation, analytical method validation, stability data under International Conference on Harmonisation (ICH) conditions, and toxicology assessment of edge activators[20]. Scale-up manufacturing presents challenges in achieving consistent particle size distribution, maintaining deformability characteristics, and controlling edge activator concentration uniformity across production batches[21]. The specialized equipment requirements and complex processing steps increase manufacturing costs and technical complexity, potentially limiting widespread commercial viability[22]. Regulatory agencies demand rigorous preclinical and clinical data demonstrating safety and efficacy beyond those required for conventional topical formulations[23].

7.3 Future Directions

Emerging research focuses upon surface functionalization of transfersomes with targeting ligands (antibodies, peptides, aptamers) to achieve tissue-specific and cell-selective drug delivery[9]. Integration of transfersomal technology with other penetration enhancement strategies including iontophoresis, sonophoresis, and microneedles may provide synergistic improvements in drug delivery efficiency[10]. Novel edge activators derived from natural sources (bile acids, plant-derived surfactants) may reduce toxicity concerns while maintaining deformability characteristics[11]. Additionally, transfersomal technology extension beyond transdermal applications to ocular, pulmonary, and nasal routes represents promising avenues for enhancing bioavailability of poorly permeable drugs[12].

8. CONCLUSION

Transfersomes represent a remarkable advancement in transdermal drug delivery technology, addressing fundamental limitations of conventional topical formulations through innovative exploitation of the skin's natural osmotic gradients. Their ultradeformable structure, composed of phospholipids and edge activators, enables passage through skin pores substantially smaller than the vesicles themselves, facilitating unprecedented penetration of therapeutically diverse molecules. The dual mechanisms of osmotic gradient-driven migration and mechanical deformability provide a passive yet highly efficient delivery system requiring neither external energy nor invasive procedures. Current pharmaceutical applications span pain management, hormone replacement therapy, cardiovascular disorders, and neurological conditions, with clinical outcomes demonstrating superior efficacy compared to conventional delivery systems. However, manufacturing complexity, stability challenges during storage, and regulatory requirements necessitate continued research and optimization. Future development of targeted transfersomal formulations, integration with complementary penetration enhancement technologies, and exploration of alternative routes of administration promise to further expand their therapeutic applications. Transfersomes exemplify the transformative potential of innovative pharmaceutical carriers in advancing non-invasive therapeutic delivery, offering patients improved safety profiles, reduced dosing frequency, and enhanced compliance while enabling more effective treatment of complex diseases.

REFERENCES

[1] Cevc, G. (1996). Ultradeformable lipid vesicles as a new tool for transdermal drug delivery. *Journal of Controlled Release*, 36(3), 157-173.

[2] Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. *Nature Biotechnology*, 26(11), 1261-1268.

[3] Touitou, E., Godin, B., & Weiss, C. (2021). Enhanced transdermal drug delivery and applications of transfersomes. *Advanced Drug Delivery Reviews*, 178, 113958.

[4] Elsayed, M. M. A., Abdallah, O. Y., Naggar, V. F., & Khalafallah, N. M. (2007). Deformable liposomes and ethosomes: Mechanism of enhanced skin delivery. *International Journal of Pharmaceutics*, 322(1-2), 60-66.

[5] Mitragotri, S., Anissimov, Y. G., Bunge, A. L., et al. (2015). Mathematical models of skin permeability: An overview. *International Journal of Pharmaceutics*, 482(1-2), 1-25.

[6] Subongkot, T., Sripramote, W., Grondahl, L., & Sanguanprasit, A. (2014). Investigation of the mechanism of enhanced skin penetration by ultradeformable liposomes with terpenes. *Journal of Pharmaceutical Sciences*, 103(7), 2045-2055.

[7] Dayan, N., & Tomlinson, D. (2005). Formulating topical agents into appropriate drug delivery systems. *Drugs*, 65(10), 1461-1469.

[8] Benson, H. A. E. (2005). Transdermal drug delivery: penetration enhancement techniques. *Current Drug Delivery*, 2(1), 23-33.

[9] Panda, D., & Pattanayak, M. (2021). Transfersomes: A promising nanoencapsulation technique. *Current Nanomedicine*, 11(2), 105-119.

[10] Riaz, M. K., Riaz, M. A., Zhang, X., et al. (2018). Surface functionalization and targeting of liposomes for brain drug delivery. *Journal of Pharmaceutical and Biomedical Analysis*, 159, 43-55.

[11] Scheuplein, R. J., & Blank, I. H. (1971). Permeability of the skin. *Physiological Reviews*, 51(4), 702-747.

[12] Lee, W. R., Shen, S. C., Kuo-Hsien, W., et al. (2005). Surfactant-mediated delivery of (±)-kojic acid through transdermal and follicular routes. *Journal of Pharmaceutical Sciences*, 94(12), 2557-2571.

[13] Walve, J. R., Znajda, A., & Andes, D. (2011). Liposomal polymyxin B for treatment of Pseudomonas aeruginosa infections. *Antimicrobial Agents and Chemotherapy*, 55(4), 1876-1879.

[14] Miatmoko, A., Suryanto, D., Kusuma, S. A. F., et al. (2022). Surfactant type determines transferosome characteristics and skin anti-aging efficacy. *Molecules*, 27(24), 8937.

[15] Chakraborty, S., & Gupta, N. V. (2022). Transdermal drug delivery systems in the management of rheumatoid arthritis: Current status and future perspectives. *Drug Delivery and Translational Research*, 12(3), 654-671.

[16] Gupta, M., Srivastava, S., & Sharma, A. K. (2020). Recent advances in transdermal drug delivery systems for diabetes management. *Nanomedicine: Nanotechnology, Biology and Medicine*, 28, 102200.

[17] Wagle, T., Sayyad, R., & Halnor, V. (2019). Microneedles: A review of transdermal drug delivery. *Journal of Drug Delivery Science and Technology*, 54, 101319.

[18] Tanwar, Y. S., & Sachdeva, S. (2016). Transdermal patches: A comprehensive review. *Indian Journal of Pharmaceutical Sciences*, 78(4), 423-433.

[19] Srivastava, R., Kumar, A., & Gupta, U. (2016). Transdermal drug delivery systems: A contemporary review. *Therapeutics and Clinical Risk Management*, 12, 949-965.

[20] Raza, R. (2015). Anatomy and physiology of skin: Understanding the barrier function for transdermal drug delivery. *International Journal of Pharmaceutical Sciences Review and Research*, 34(2), 156-167.